Evidence map›Paper›PMID 35174094›Full record

ArticleFrontiers in oncology2022

Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity.

Marius Tham, Hans-Jürgen Stark, Anna Jauch, Catherine Harwood, Elizabeth Pavez Lorie, Petra Boukamp

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Marius ThamDepartment of Genetics of Skin Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hans-Jürgen StarkDepartment of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Anna JauchInstitute of Human Genetics, University Heidelberg, Heidelberg, Germany.
Catherine HarwoodDepartment of Dermatology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
Elizabeth Pavez LorieIUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany.
Petra BoukampDepartment of Genetics of Skin Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Research Center · DEHeidelberg University · DELeibniz Institute of Environmental Medicine · DEQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The BRAF inhibitor vemurafenib, approved for treating patients with BRAF V600E-mutant and unresectable or metastatic melanomas, rapidly induces cutaneous adverse events, including hyperkeratotic skin lesions and cutaneous squamous cell carcinomas (cSCC). To determine, how vemurafenib would provoke these adverse events, we utilized long-term

Indexed as

cutaneous adverse effectsdegradomematrix metalloproteinaseMEK inhibitionorganotypic skin cancer modelskin cancertumor invasionvemurafenib

Identifiers

PMID35174094
PMCPMC8842679
OpenAlexW4210509865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.